| scholarly article | Q13442814 |
| P50 | author | Jorge Reis-Filho | Q23892845 |
| Richard Marais | Q30118915 | ||
| Nathalie Dhomen | Q37379933 | ||
| Veronique Delmas | Q43077141 | ||
| Catrin Pritchard | Q61808113 | ||
| P2093 | author name string | Lionel Larue | |
| Robert Hayward | |||
| Kay Savage | |||
| Silvy da Rocha Dias | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 294-303 | |
| P577 | publication date | 2009-04-01 | |
| P1433 | published in | Cancer Cell | Q280018 |
| P1476 | title | Oncogenic Braf induces melanocyte senescence and melanoma in mice | |
| P478 | volume | 15 |
| Q42154833 | A Micro-RNA Connection inBRafV600E-Mediated Premature Senescence of Human Melanocytes |
| Q36945927 | A New p53 Target Gene, RKIP, Is Essential for DNA Damage-Induced Cellular Senescence and Suppression of ERK Activation |
| Q36262832 | A Novel Fully Humanized 3D Skin Equivalent to Model Early Melanoma Invasion. |
| Q38840793 | A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity |
| Q34755077 | A high-content screening assay for small-molecule modulators of oncogene-induced senescence. |
| Q48147976 | A histopathological classification system of Tyr::NRASQ61K murine melanocytic lesions: A reproducible simplified classification. |
| Q39150145 | A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. |
| Q41967375 | A mouse model of melanoma driven by oncogenic KRAS. |
| Q36073207 | A murine model for the development of melanocytic nevi and their progression to melanoma |
| Q53105517 | A mutation in the Cdon gene potentiates congenital nevus development mediated by NRAS(Q61K). |
| Q37815139 | A new era: melanoma genetics and therapeutics |
| Q36993393 | A role for c-Abl in cell senescence and spontaneous immortalization |
| Q41876426 | A screen for morphological complexity identifies regulators of switch-like transitions between discrete cell shapes |
| Q99566645 | A smooth muscle-derived, BRAF-driven mouse model of gastrointestinal stromal tumor (GIST): evidence for an alternative GIST cell-of-origin |
| Q52562647 | A step-by-step microRNA guide to cancer development and metastasis. |
| Q36301027 | ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment |
| Q39233356 | AZT on telomerase activity and cell proliferation in HS 839.T melanoma cells |
| Q34253185 | Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis |
| Q39362670 | Absence of distinguishing senescence traits in human melanocytic nevi |
| Q49787772 | Activation of Grm1 expression by mutated BRaf (V600E) in vitro and in vivo |
| Q41680604 | Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence. |
| Q37818577 | Advances in melanoma senescence and potential clinical application. |
| Q97543614 | After Nf1 loss in Schwann cells, inflammation drives neurofibroma formation |
| Q33769541 | An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition |
| Q36464502 | An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background |
| Q37847257 | Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma |
| Q35007125 | Antagonistic TSC22D1 variants control BRAFE600-induced senescence |
| Q38127412 | Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics |
| Q34375732 | Are oncogenes sufficient to cause human cancer? |
| Q36822126 | Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition |
| Q21134717 | B-RAF Mutant Alleles Associated with Langerhans Cell Histiocytosis, a Granulomatous Pediatric Disease |
| Q36692818 | BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. |
| Q36418729 | BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma |
| Q35090029 | BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model |
| Q34162272 | BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas |
| Q58776439 | BRAF somatic mutation contributes to intrinsic epileptogenicity in pediatric brain tumors |
| Q42733647 | BRAF targeted therapy changes the treatment paradigm in melanoma |
| Q28543370 | BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications |
| Q37772444 | BRAF, a target in melanoma: implications for solid tumor drug development |
| Q38916660 | BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress |
| Q34374407 | BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines |
| Q38520679 | BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation |
| Q36021702 | BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration |
| Q89499162 | Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation |
| Q41995284 | Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression |
| Q38371675 | Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer |
| Q57571832 | CDK4 inhibitors an emerging strategy for the treatment of melanoma |
| Q35390334 | Cancer stem cells as a target population for drug discovery |
| Q36096239 | Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer |
| Q35947022 | Cellular senescence and cancer chemotherapy resistance |
| Q26773500 | Cellular senescence in aging and age-related disease: from mechanisms to therapy |
| Q37678205 | Cellular senescence in osteoarthritis pathology. |
| Q33725691 | Changed genome heterochromatinization upon prolonged activation of the Raf/ERK signaling pathway |
| Q91834191 | Chromatin remodellers Brg1 and Bptf are required for normal gene expression and progression of oncogenic Braf-driven mouse melanoma |
| Q35901458 | Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis |
| Q38809327 | Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma |
| Q48005711 | Concerns regarding BRAF testing algorithm: reply from authors. |
| Q30499131 | Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome |
| Q36001219 | Cooperative interactions of BRAF V600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy |
| Q34338564 | Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis |
| Q84392766 | Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis |
| Q95584389 | Craniopharyngioma |
| Q26782090 | Cross-species models of human melanoma |
| Q33553465 | Cuprous oxide nanoparticle-inhibited melanoma progress by targeting melanoma stem cells |
| Q26781652 | Current State of Animal (Mouse) Modeling in Melanoma Research |
| Q27022355 | Current and future trials of targeted therapies in cutaneous melanoma |
| Q88795679 | Cutaneous Melanoma-A Long Road from Experimental Models to Clinical Outcome: A Review |
| Q37568972 | Cutaneous melanoma in the era of molecular profiling |
| Q38177036 | Cyclin-dependent kinases as therapeutic targets in melanoma |
| Q36134167 | Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. |
| Q38120311 | DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma. |
| Q34646614 | Dabrafenib and its potential for the treatment of metastatic melanoma |
| Q47164137 | Degree of Tissue Differentiation Dictates Susceptibility to BRAF-Driven Colorectal Cancer |
| Q41423088 | Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging. |
| Q52838410 | Detection of Oncogene-Induced Senescence In Vivo |
| Q37384015 | Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. |
| Q54655468 | Differential roles of the pRb and Arf/p53 pathways in murine naevus and melanoma genesis. |
| Q33649569 | Dormancy of metastatic melanoma |
| Q39047097 | Dynamic interplay between autophagic flux and Akt during melanoma progression in vitro |
| Q100527978 | Dynamics of nevus development implicate cell cooperation in the growth arrest of transformed melanocytes |
| Q47224965 | ETS1, nucleolar and non-nucleolar TERT expression in nevus to melanoma progression |
| Q38943303 | Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability. |
| Q37440364 | Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines |
| Q34398036 | Efficient gene expression profiling of laser-microdissected melanoma metastases. |
| Q27851952 | Elucidating distinct roles for NF1 in melanomagenesis |
| Q37691441 | Emerging MEK inhibitors. |
| Q38729438 | Emerging roles of lncRNAs in senescence. |
| Q38602788 | Emerging targets for combination therapy in melanomas |
| Q39467208 | Energy parasites trigger oncogene mutation |
| Q41438730 | Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths |
| Q34180117 | Exploiting tumor cell senescence in anticancer therapy |
| Q35963419 | Expression of oncogenic BRAFV600E in melanocytes induces Schwannian differentiation in vivo |
| Q36533041 | Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases |
| Q39312161 | Focus on cutaneous and uveal melanoma specificities. |
| Q37999967 | From genes to drugs: targeted strategies for melanoma |
| Q39694616 | Gatekeeper mutations mediate resistance to BRAF-targeted therapies. |
| Q33895966 | Genetic and environmental melanoma models in fish |
| Q39329577 | Genetically engineered mouse models of melanoma |
| Q28085036 | Genetics of melanocytic nevi |
| Q36563659 | Genetics of melanoma |
| Q38589518 | Genetics of melanoma progression: the rise and fall of cell senescence |
| Q88552258 | Genetics of metastasis: melanoma and other cancers |
| Q90590903 | Genistein inhibits proliferation and induces senescence in neonatal mouse pituitary gland explant cultures |
| Q34697738 | HIRA orchestrates a dynamic chromatin landscape in senescence and is required for suppression of neoplasia |
| Q92160659 | Heterozygous loss of keratinocyte TRIM16 expression increases melanocytic cell lesions and lymph node metastasis |
| Q43511598 | Histopathological atlas and proposed classification for melanocytic lesions in Tyr::NRas(Q61K) ; Cdkn2a(-/-) transgenic mice. |
| Q45166921 | Human Nevi: No Longer Precursors of Melanomas? |
| Q43205265 | Human nevi lack distinguishing senescence traits. |
| Q37850873 | Hypoxia and Senescence: The Impact of Oxygenation on Tumor Suppression |
| Q36225861 | Identification of a novel role of RING finger protein 11 promoting the metastasis of murine melanoma cells |
| Q70347358 | Immunohistochemical Investigation of Mutant BRAF V600E in Common Pigmented Skin Neoplasms, Study on a Sample of Iranian Patients |
| Q36750622 | Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. |
| Q40333990 | Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo |
| Q24629400 | In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma |
| Q48382418 | Inducible expression of (V600E) Braf using tyrosinase-driven Cre recombinase results in embryonic lethality. |
| Q42775668 | Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6 |
| Q37660341 | Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma |
| Q36190681 | Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis |
| Q35060446 | Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas |
| Q35474544 | Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling |
| Q30491014 | Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination |
| Q38578526 | Is reliance on mitochondrial respiration a "chink in the armor" of therapy-resistant cancer? |
| Q91142521 | KLF9-dependent ROS regulate melanoma progression in stage-specific manner |
| Q37815135 | KRAS and BRAF: drug targets and predictive biomarkers |
| Q24298749 | Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF |
| Q38868299 | Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci |
| Q37667080 | Liquid Biopsies for Assessing Metastatic Melanoma Progression |
| Q33812469 | Long non-coding RNA BANCR promotes proliferation in malignant melanoma by regulating MAPK pathway activation |
| Q37025145 | Loss of ARF sensitizes transgenic BRAFV600E mice to UV-induced melanoma via suppression of XPC. |
| Q34130042 | Loss of nuclear receptor RXRα in epidermal keratinocytes promotes the formation of Cdk4-activated invasive melanomas |
| Q38040353 | MAP kinase signaling and inhibition in melanoma |
| Q38081986 | MITF, the Janus transcription factor of melanoma. |
| Q21245465 | Main roads to melanoma |
| Q57664796 | Malignant Melanoma–a Genetic Overview |
| Q39169776 | Mechanisms of Drug Resistance in Melanoma |
| Q52321974 | Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place. |
| Q37948057 | Mechanisms of aneuploidy induction by RAS and RAF oncogenes |
| Q37606387 | Melanocytes in development and cancer |
| Q38730348 | Melanocytic nevi and melanoma: unraveling a complex relationship |
| Q36384802 | Melanoma Prevention Using Topical PBISe |
| Q92969193 | Melanoma Progression Inhibits Pluripotency and Differentiation of Melanoma-Derived iPSCs Produces Cells with Neural-like Mixed Dysplastic Phenotype |
| Q54615570 | Melanoma and viagra: an unexpected connection. |
| Q37360062 | Melanoma-initiating cells: a compass needed. |
| Q47227422 | Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells |
| Q21284811 | Melanoma: from melanocyte to genetic alterations and clinical options |
| Q27024061 | Melanoma: from mutations to medicine |
| Q47171898 | Mesenchymal Stem Cells Secretory Responses: Senescence Messaging Secretome and Immunomodulation Perspective. |
| Q26782068 | Mitochondrial Dysfunction and Disturbed Coherence: Gate to Cancer |
| Q37069214 | Modeling Melanoma In Vitro and In Vivo. |
| Q84372276 | Modeling epidermal melanoma in mice: moving into new realms but with unexpected complexities |
| Q37943839 | Modelling melanoma in mice. |
| Q38093446 | Molecular and cellular pathogenesis of melanoma initiation and progression. |
| Q34612281 | Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma |
| Q39214879 | Monitoring Oncogenic B-RAF-Induced Senescence in Melanocytes |
| Q39640218 | Mouse melanoma models and cell lines |
| Q54977969 | Mps1 is associated with the BRAFV600E mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma. |
| Q91874987 | Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy |
| Q37705228 | Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032. |
| Q36862768 | Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response |
| Q50420763 | Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition. |
| Q92627552 | Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance |
| Q27852445 | NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi. |
| Q37984547 | Narrowing the knowledge gaps for melanoma |
| Q54622331 | Neonatal UVB exposure accelerates melanoma growth and enhances distant metastases in Hgf-Cdk4(R24C) C57BL/6 mice. |
| Q37874368 | Never-ageing cellular senescence |
| Q40546752 | Nevus senescence. |
| Q34986188 | New horizons in melanoma treatment: targeting molecular pathways |
| Q37589059 | New insights into the molecular pathogenesis of langerhans cell histiocytosis |
| Q38050461 | New therapeutical strategies in the treatment of metastatic disease. |
| Q36150711 | Non-germline genetically engineered mouse models for translational cancer research |
| Q35810716 | Novel ARF/p53-independent senescence pathways in cancer repression. |
| Q37971404 | Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis |
| Q34437857 | Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway. |
| Q37950784 | Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence |
| Q40159365 | Oncogene-Expressing Senescent Melanocytes Up-Regulate MHC Class II, a Candidate Melanoma Suppressor Function |
| Q37890974 | Oncogene-induced senescence and its role in tumor suppression. |
| Q37784324 | Oncogene-induced senescence: the bright and dark side of the response |
| Q37948288 | Oncogene‐induced senescence and melanoma: where do we stand? |
| Q39145156 | Oncogenic B-RafV600E abrogates the AKT/B-Raf/Mps1 interaction in melanoma cells |
| Q36793719 | Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF |
| Q36957578 | Oncogenic BRAF-Mediated Melanoma Cell Invasion |
| Q90349565 | Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis |
| Q39114297 | Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress. |
| Q50790188 | Origin of Mouse Melanomas |
| Q43298157 | Overcoming resistance to BRAF inhibitors. |
| Q36224716 | PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma. |
| Q46095420 | PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation |
| Q38844565 | PIM1 induces cellular senescence through phosphorylation of UHRF1 at Ser311. |
| Q38981503 | PKCι depletion initiates mitotic slippage-induced senescence in glioblastoma |
| Q39076276 | PTEN functions as a melanoma tumor suppressor by promoting host immune response |
| Q38176686 | Papillary thyroid microcarcinoma: how to diagnose and manage this epidemic? |
| Q34978580 | Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma |
| Q47927484 | Pathways from senescence to melanoma: focus on MITF sumoylation. |
| Q37777015 | Pathways of oncogene-induced senescence in human melanocytic cells |
| Q36526919 | Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104) |
| Q38981612 | Phosphoproteome dynamics in onset and maintenance of oncogene-induced senescence |
| Q39376909 | Phosphorylation of Mps1 by BRAFV600E prevents Mps1 degradation and contributes to chromosome instability in melanoma |
| Q26766708 | Phytochemicals for the Management of Melanoma |
| Q34838382 | Pirin inhibits cellular senescence in melanocytic cells. |
| Q39609077 | Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression |
| Q47718098 | Postnatal Expression of BRAFV600E Does Not Induce Thyroid Cancer in Mouse Models of Thyroid Papillary Carcinoma |
| Q37722851 | Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. |
| Q37893959 | Pro-senescence therapy for cancer treatment |
| Q30657002 | RAB7 counteracts PI3K-driven macropinocytosis activated at early stages of melanoma development |
| Q93138003 | RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance |
| Q50068807 | RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. |
| Q41808393 | RAS, cellular senescence and transformation: the BRCA1 DNA repair pathway at the crossroads |
| Q33697210 | RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion |
| Q24316181 | Raf family kinases: old dogs have learned new tricks |
| Q28237793 | Raf kinases in cancer-roles and therapeutic opportunities |
| Q48366202 | Rapid melanoma induction in mice expressing oncogenic BrafV600E using Mitf-cre |
| Q38556243 | Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models |
| Q37525082 | Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation |
| Q34044908 | Recent advances on skin-resident stem/progenitor cell functions in skin regeneration, aging and cancers and novel anti-aging and cancer therapies |
| Q49887919 | Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors |
| Q27024320 | Reconstructing skin cancers using animal models |
| Q42128543 | Reducing prostaglandin E2 production to raise cancer immunogenicity |
| Q61797822 | Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment |
| Q39980994 | Regulation of BRAF protein stability by a negative feedback loop involving the MEK-ERK pathway but not the FBXW7 tumour suppressor. |
| Q39584006 | Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells. |
| Q34665706 | Regulation of Senescence in Cancer and Aging |
| Q37801346 | Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. |
| Q36703612 | Rho-associated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis |
| Q37558112 | Role of the BrafV637E mutation in hepatocarcinogenesis induced by treatment with diethylnitrosamine in neonatal B6C3F1 mice |
| Q34966603 | Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging |
| Q39402835 | Sef Downregulation by Ras Causes MEK1/2 to Become Aberrantly Nuclear Localized Leading to Polyploidy and Neoplastic Transformation |
| Q54576054 | Selective loss of wild-type p16(INK4a) expression in human nevi. |
| Q37943564 | Senescence and pre-malignancy: How do tumors progress? |
| Q37168870 | Senescence at a glance |
| Q36903843 | Senescence in tumours: evidence from mice and humans |
| Q33652889 | Senescence is an endogenous trigger for microRNA-directed transcriptional gene silencing in human cells |
| Q39341975 | Senescent fibroblasts in melanoma initiation and progression: an integrated theoretical, experimental, and clinical approach |
| Q39128830 | Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles |
| Q34262532 | Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study |
| Q34490844 | Silencing of Diphthamide Synthesis 3 (Dph3) Reduces Metastasis of Murine Melanoma |
| Q33533313 | Skeletal muscle phenotypically converts and selectively inhibits metastatic cells in mice |
| Q35578577 | Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation |
| Q39693657 | Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study |
| Q47104545 | Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma. |
| Q52657766 | Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy. |
| Q89686121 | Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma |
| Q39048659 | Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth |
| Q35111733 | Superficial spreading-like melanoma in Arf(-/-)::Tyr-Nras(Q61K)::K14-Kitl mice: keratinocyte Kit ligand expression sufficient to "translocate" melanomas from dermis to epidermis |
| Q50794958 | Suppression of microphthalmia-associated transcription factor, but not NF-kappa B sensitizes melanoma specific cell death. |
| Q39170489 | Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence |
| Q33578398 | Synthetic lethality: emerging targets and opportunities in melanoma |
| Q53232884 | TP53 in the UV spotlight: a bona fide driver of melanoma |
| Q52664598 | TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer |
| Q35022501 | TSH signaling overcomes B-RafV600E-induced senescence in papillary thyroid carcinogenesis through regulation of DUSP6. |
| Q51891410 | Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress |
| Q34005661 | Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice. |
| Q36590628 | Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling |
| Q38098888 | Targeting MAPK pathway in melanoma therapy |
| Q64263350 | Targeting MC1R depalmitoylation to prevent melanomagenesis in redheads |
| Q27026323 | Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond |
| Q39074281 | Targeting protein kinase-b3 (akt3) signaling in melanoma |
| Q40007423 | Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma |
| Q37745182 | Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail |
| Q50040360 | Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma. |
| Q37945533 | The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both? |
| Q26747247 | The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer |
| Q37336605 | The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma |
| Q37871660 | The PKB/FOXO switch in aging and cancer |
| Q39018419 | The Regulation of Cellular Functions by the p53 Protein: Cellular Senescence |
| Q36762792 | The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects |
| Q34288983 | The essence of senescence |
| Q34287452 | The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα |
| Q38756275 | The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies |
| Q34202289 | The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments |
| Q21559479 | The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells |
| Q34414166 | The p16INK4A tumor suppressor regulates cellular oxidative stress |
| Q59600708 | The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases |
| Q48223617 | The protective role of DOT1L in UV-induced melanomagenesis |
| Q104517955 | The receptor DNGR-1 signals for phagosomal rupture to promote cross-presentation of dead-cell-associated antigens |
| Q39372069 | The renal v‐ATPase a4 subunit is expressed in specific subtypes of human gliomas |
| Q37931402 | The role of mitogen- and stress-activated protein kinase pathways in melanoma |
| Q38238861 | The roles of microphthalmia-associated transcription factor and pigmentation in melanoma |
| Q91187770 | Thymine DNA glycosylase as a novel target for melanoma |
| Q34533804 | Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice |
| Q50642659 | Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by β-catenin activity |
| Q58105812 | Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma |
| Q88731404 | Two-Step Senescence-Focused Cancer Therapies |
| Q39330282 | Ubiquitination in melanoma pathogenesis and treatment. |
| Q33955442 | Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53 |
| Q60038449 | Ultraviolet radiation–induced DNA damage is prognostic for outcome in melanoma |
| Q55967623 | Unveiling skin macrophage dynamics explains both tattoo persistence and strenuous removal |
| Q42059658 | V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a |
| Q58001127 | V600EBraf::Tyr-CreERT2::K14-Kitl Mice Do Not Develop Superficial Spreading-Like Melanoma: Keratinocyte Kit Ligand Is Insufficient to “Translocate” V600EBraf-Driven Melanoma to the Epidermis |
| Q34641609 | Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma |
| Q39770574 | Viral oncolysis that targets Raf-1 signaling control of nuclear transport. |
| Q92095616 | Virtual biopsy using MRI radiomics for prediction of BRAF status in melanoma brain metastasis |
| Q83193419 | What is a good model for melanoma? |
| Q51518956 | Wnt signaling in cancer. |
| Q37218527 | Wnt signaling potentiates nevogenesis |
| Q82244659 | Xmrk in medaka: a new genetic melanoma model |
| Q34965452 | mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation |
| Q93051485 | miR-146a Controls Immune Response in the Melanoma Microenvironment |
| Q34619395 | miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2. |
| Q36088890 | p21 loss blocks senescence following Apc loss and provokes tumourigenesis in the renal but not the intestinal epithelium |
| Q48026380 | p53 loss does not permit escape from BrafV600E-induced senescence in a mouse model of lung cancer |
Search more.